Lyra Therapeutics, Inc.

NasdaqGM:LYRA Rapport sur les actions

Capitalisation boursière : US$16.9m

Lyra Therapeutics Résultats passés

Passé contrôle des critères 0/6

Lyra Therapeutics's earnings have been declining at an average annual rate of -34.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 51.7% per year.

Informations clés

-34.1%

Taux de croissance des bénéfices

92.5%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie6.0%
Taux de croissance des recettes51.7%
Rendement des fonds propres-327.3%
Marge nette-5,570.9%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Ventilation des recettes et des dépenses

Comment Lyra Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGM:LYRA Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 242-101200
31 Mar 242-69200
31 Dec 232-63190
30 Sep 231-62190
30 Jun 231-61170
31 Mar 231-60180
31 Dec 221-55180
30 Sep 222-55180
30 Jun 221-51170
31 Mar 221-48160
31 Dec 210-44140
30 Sep 210-37160
30 Jun 210-3214-5
31 Mar 210-2611-3
31 Dec 200-22100
30 Sep 200-2083
30 Jun 200-18611
31 Mar 200-17512
31 Dec 190-17412
31 Dec 181-645

Des revenus de qualité: LYRA is currently unprofitable.

Augmentation de la marge bénéficiaire: LYRA is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: LYRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.

Accélération de la croissance: Unable to compare LYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: LYRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement des fonds propres

ROE élevé: LYRA has a negative Return on Equity (-327.31%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé